Table 1.

Differentially expressed immune checkpoints (receptors and ligands) in tumor-infiltrating immune cells from breast tumor explants in response to anti-PD-1, PD-L1, or anti-TIM-3 compared to non-treated cells.

Immune Checkpoints	Anti-PD-1	Anti-PDL1	Anti-TIM-3
Upregulated	HAVCR2 (TIM-3 gene), CTLA4, CD96, ICOS and CD160	LAG3, PDCD1 (PD-1 gene), CTLA4, CD244, CD96, HAVCR2, CD160, ICOS, CD274, KLRG1, BTLA, KIR2DS4, TNFRSF4 (OX40 ligand) and LGALS9	ICOS, ICOSLG, PDCD1, TIGIT, CTLA4, CD96, CD160, CD244, KLRG1, TNFRSF4, BTLA, CD274, TNFRSF9 and KIR2DS4
Downregulated	LAG3, CD274 (PD-L1), ICOSLG (ICOS ligand), TIGIT, LGALS9 (galectin-9) and KIR2DS4	ICOSLG and TNFRSF9 (CD137)	CD274 and LGALS9